Neuraptive Therapeutics announces FDA has granted fast track designation to NTX-001 clinical development programme to treat peripheral nerve injuries

This article was originally published here

FDA Fast Track is a program designed to facilitate and expedite the development and review of a new drugs that demonstrates the potential to address an unmet medical

The post Neuraptive Therapeutics announces FDA has granted fast track designation to NTX-001 clinical development programme to treat peripheral nerve injuries appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply